Pharmacokinetics of aztreonam after intravenous administration in foals.

The experiment investigates the pharmacokinetics of intravenous aztreonam in foals. Aztreonam is a synthetic antibiotic effective against many gram-negative bacteria and was evaluated for its safety and tolerability in young horses in an attempt to find an alternative to drugs that can have adverse side effects.

Research Context

• The study emerged from the need to manage sepsis in foals, which is frequently caused by a variety of gram-negative bacteria found in the environment.
• While antibiotics like aminoglycosides and fluoroquinolones are often used, concerns about potential kidney toxicity or permanent cartilage damage limit their applications.
• The researchers chose to investigate aztreonam due to its ability to treat gram-negative bacteria without the aforementioned side effects.

The Experiment

• The research involved administering intravenous aztreonam to five healthy weanling foals aged between 2-3 months, allowing for potential human-to-animal pharmacokinetic comparisons.
• The study hypothesised that aztreonam would be safe and well-tolerated in foals, with the drug’s pharmacokinetics resembling those described in human patients.
• The antibiotic was administered at a dosage of 30 mg/kg, diluted with sterile water and delivered into the animal over a five-minute period through catheterization.
• Blood samples were taken over a 24-hour period after administration, with aztreonam plasma concentrations measured using high-performance liquid chromatography.

Results and Observations

• All five foals tolerated the infusion of aztreonam well, although two of the five developed watery diarrhea within the first 24 hours after administration.
• No significant changes in complete blood count and serum biochemical profiles were observed one week after drug administration, suggesting the antibiotic has little effect on these parameters.
• The drug showed a rapid diminution with its mean plasma concentration decreasing below detectable limits within 12 hours post-infusion for four of the five foals, similar to human patients.

Conclusions

• The study provides an encouraging perspective on the use of aztreonam in treating sepsis in foals.
• Though the small sample size may limit the generalizability of results, the findings lay the groundwork for larger, more comprehensive studies to understand the safety profile and pharmacokinetic characteristics of aztreonam in equines further.